ArticleEndocrine journal2026
ZFP36-ferroptosis axis as a key renal protective pathway in diabetic kidney disease.
Article in Endocrine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic Kidney Disease (DKD) is strongly related to ferroptosis, an iron-dependent form of programmed cell death characterized by the accumulation of lipid peroxides. While ferroptosis is a pivotal mediator in DKD pathogenesis, its upstream regulatory mechanism remains poorly defined, thus impeding the development of targeted therapeutic strategies. In this study, by integrating multi-omics clinical data (GSE96804 and GSE104954) and combining machine learning algorithms, the RNA-binding protein ZFP36 was screened out as the core regulatory factor of ferroptosis in DKD. The results revealed that the expression level of ZFP36 in the DKD group was significantly lower than that in the normal group. Functional experiments demonstrated that overexpression of ZFP36 could significantly alleviate lipid peroxidation, iron ion accumulation, and cellular fibrosis, thereby inhibiting ferroptosis and alleviating kidney damage. Transcriptome analysis further revealed that ZFP36 regulated key genes related to oxidative stress and iron metabolism. Additionally, molecular docking simulations revealed strong binding affinity between ZFP36 and bioactive natural products such as berberine and astragalus, providing a potential mechanism for its renal protective effect. Overall, ZFP36 was hereby established as an important inhibitor of ferroptosis in DKD, highlighting its potential as both a biomarker and a therapeutic target for its precision diagnosis and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.